Drug Approval | June 17, 2024
Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
EDQM has also issued a Certificate of Suitability for Allopurino
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Subscribe To Our Newsletter & Stay Updated
